The results may reflect differences in pharmacokinetic and pharmacodynamic properties, trial design or drug differences
In June 2025, Amgen announced positive Phase 2 trial results for MariTide showing up to ~20% weight loss in obese patients and ~17% in type 2 diabetes patients, presented at the ADA 85th scientific sessions
J Agric Food Chem 67:51135121
Commonly a chelating agent will mobilize the most readily available metals first, typically in the plasma, kidney, liver and then to a lesser extent bone and central nervous system
In the phase 2 dose-finding trial involving 706 participants, nausea rates varied dramatically by dose
Most people can take this combination safely, but youll need regular blood tests to check potassium levels and kidney function